-+ 0.00%
-+ 0.00%
-+ 0.00%
PDS BIOTECH ANNOUNCES PUBLICATION OF VERSATILE-002 PHASE 2 CLINICAL TRIAL RESULTS OF PDS0101 WITH PEMBROLIZUMAB IN HPV16-POSITIVE RECURRENT AND/OR METASTATIC (R/M) HEAD AND NECK CANCER IN JAMA ONCOLOGY
Share

Please log in to view news

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending